New ebook: Before You Borrow, how lenders decide and how to get your business loan approved. Get it for $7.99 →
New ebookHow to Research Like a Wall Street AnalystFind original sources, analyze trends, build your own insightsGet it now →
Markets
Real businesses. Bigger perspective. · Wed, Nov 18, 2026News. Tools. Scores. Games. Free.The Morning Chronicle
Donate BTCOpen dDashboard

Stocks

Sellas stock nearly triples as its leukemia vaccine cuts risk of death 41% in a Phase 3 trial

SELLAS says galinpepimut-S met its primary survival goal in the REGAL trial: 24.0 months median survival versus 14.7 on best available treatment. The result is topline, and the p-value is 0.035.

Chart of SELLAS Life Sciences stock over six months showing a jump on Nov. 17, 2026
SELLAS (SLS) traded near $20.22 on Nov. 17, 2026. Chronicle chart from Yahoo Finance data.

SELLAS Life Sciences (NASDAQ: SLS) said Tuesday that its cancer vaccine galinpepimut-S, or GPS, met the primary endpoint of the pivotal Phase 3 REGAL trial in acute myeloid leukemia (AML). The shares were trading at $20.22 at 12:41 p.m. ET, up 170.7% from Monday's $7.47 close, according to Nasdaq quote data. Bloomberg and Benzinga both described the move as the stock tripling at its peak; Nasdaq showed a session range of $16.72 to $24.89.

What the company reported

In its press release filed with the SEC, SELLAS said:

  • GPS cut the risk of death by 41%, a hazard ratio of 0.59, with a two-sided p-value of 0.035.
  • Median overall survival was 24.0 months for GPS versus 14.7 months for investigator's choice of best available treatment.
  • The patients had AML in second or later complete remission and could not have, or could not undergo, an allogeneic stem cell transplant. GPS was given as maintenance monotherapy.
  • The analysis was run after the pre-specified 80 deaths, under the trial's statistical plan.
  • Safety was "generally well tolerated," with mostly grade 1 or 2 events, mainly injection-site reactions, and no new safety signals.
SELLAS, 6M. Chart by TradingView.

What it means, and what it does not

A median gain of about 9.3 months (24.0 less 14.7, our arithmetic) in a group with few options is a large effect if it holds. But three caveats matter for anyone reading the stock move:

  • It is topline data. The company says secondary endpoints and other pre-specified analyses are still being evaluated and will be presented at a medical meeting and submitted for peer review. Nobody outside the company has seen the full dataset.
  • The p-value is close to the usual line. A p of 0.035 clears the conventional 0.05 threshold, but not by much. Small trials with few events can move on a handful of patients.
  • The regulatory path is not set. SELLAS says it plans to meet the FDA about an "accelerated filing strategy" and is preparing a Biologics License Application for the first half of 2027. A meeting is not an agreement, and the FDA has not commented in the filing.

The market side

Nasdaq lists a market value of about $4.13 billion at the current price, and a 52-week low of $1.39. For a clinical-stage company, a first Phase 3 win can change how it raises money: the share price now sets the terms for any stock offering or partnership. Whether SELLAS does either is not in the filing, and we do not report it as a plan.

For small-cap biotech holders, the rest of the week is about the webcast replay, any FDA feedback and whether the full secondary-endpoint data match the headline. Related reading: more stock news.

Sources: SELLAS 8-K, Nov. 17, 2026; SELLAS filings on SEC EDGAR; price data from Nasdaq, read at 12:41 p.m. ET; Bloomberg and Benzinga headlines. Investigational therapies are not approved by the FDA. This is market information, not investment advice.

Want your business to be the answer?

Get a full package of articles about your business, built so customers, Google and AI assistants can find you.

Get featured
New ebook from The Company ChronicleHow to Research Like a Wall Street AnalystFind original sources, analyze trends, and build your own insights. 36 pages with worksheets.Get the ebook · $29Instant PDF download
New ebook from The Company ChronicleHow to Research Like a Wall Street AnalystFind original sources, analyze trends, and build your own insights. 36 pages with worksheets.Get the ebook · $29Instant PDF download

Business Spotlight

Want us to publish your business?

Our team writes and publishes articles about your business on The Company Chronicle every month, with a link to your website. Plans from $30 a month, cancel anytime.

Publish with us

The Chronicle directory

What are you into?

The Chronicle, coast to coast

Every corner has a story.

The full Chronicle illustration